LBA3_PR gynaecological cancers A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA…

Overview of attention for article published in Annals of Oncology, October 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

So far, Altmetric has seen 1 news story.

We have never seen such large benefits in progression-free survival in recurrent ovarian cancer.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.